Health ❯ Healthcare ❯ Pharmacology

Anticoagulants

Rivaroxaban Direct Oral Anticoagulants Apixaban vs Warfarin Asundexian Factor XIa Inhibitors Apixaban Non-vitamin K Antagonist Oral Anticoagulants Edoxaban NOACs

Milvexian Fails to Cut Heart Attack, Stroke or Death After Acute Coronary Syndrome

The 25 mg twice‑daily dose produced anticoagulant effects but did not reduce ischemic events or raise intracranial or fatal bleeding rates.

Edoxaban Shows No Net Benefit for Atrial Fibrillation Patients After Intracranial Haemorrhage

Apixaban Cuts Bleeding Versus Rivaroxaban in Venous Thrombosis, NEJM Head-to-Head Trial Finds

Asundexian Cuts Recurrent Stroke 26% Without More Major Bleeding in Phase III